(TheNewswire)
Toronto, Ontario – TheNewswire – December 15, 2020 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) held its Annual General & Special Shareholders meeting via conference call yesterday, December 14, 2020.
All resolutions considered and voted upon by shareholders were approved by a greater than 95% majority of shareholder votes.
All Board of Directors nominees were elected with greater than 99% majority of the shareholder votes.
The Shareholders approved an amendment to the Company’s articles to change the province in which the Company’s registration is located from Alberta to Ontario.
The CEO slide presentation is available on the Ventripoint website at: https://179b49c1-1e6c-43e8-8e81-82a04e05b727.filesusr.com/ugd/8e5203_3c104b726d68413f9f55383b6fe60978.pdf .
In addition, A CEO video presentation can be viewed at : https://ca.paidpromotionalmessages.com/companies/news/936483/ventripoint-diagnostics-recent-grants-gives-company-runway-to-execute-on-sales-plans-in-2021-936483.html
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Dr. George Adams
Email : gadams@ventripoint.com
Phone: 519-803-6937